|Bid||19.00 x 1100|
|Ask||19.18 x 1000|
|Day's Range||19.01 - 21.89|
|52 Week Range||10.19 - 25.61|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.33|
NEW HAVEN, Conn., Feb. 07, 2019 -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that it will.
Many diseases tied to rogue proteins are “undruggable.” That may change as pharmaceutical companies are now testing a process called protein degradation in drug development.
Arvinas, Inc. (ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for ARV-110, an oral androgen receptor (AR) PROTAC™ protein degrader, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Arvinas expects to begin enrollment of a Phase 1 clinical trial for ARV-110 in the first quarter of this year. “This IND clearance is a key step forward for Arvinas and for the field of protein degradation,” said John Houston, Ph.D., President and CEO of Arvinas.
NEW HAVEN, Conn., Dec. 07, 2018 -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today presented.
President and CEO of Arvinas Inc (NASDAQ:ARVN) John G Houston bought 30,000 shares of ARVN on 10/01/2018 at an average price of $16 a share.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...